RLAY · Relay Therapeutics, Inc.
$19.76
+0.32 (+1.65%)
At close · Aug 24
Market Cap
$4.33B
Shares
219.14M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$15.36M
+53.4%
FY2025
Net Income
-$276.48M
+18.1%
FY2025
Operating Margin
-1971.59%
+1750.5pp
FY2025
Diluted EPS
-$1.61
+31.8%
FY2025
Operating Cash Flow
-$235.46M
+5.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $10.35M | $15.36M | $10.01M | $25.55M | $1.38M | $3.03M | $82.65M | — | |
| $270.72M | $261.38M | $319.09M | $330.02M | $246.36M | $172.65M | $99.86M | $70.31M | |
| $50.06M | $56.71M | $76.59M | $74.95M | $65.98M | $57.39M | $38.59M | $13.74M | |
| $320.79M | $318.09M | $382.48M | $398.55M | $300.66M | $367.73M | $138.45M | $84.05M | |
| -$310.44M | -$302.74M | -$372.47M | -$373M | -$299.28M | -$364.7M | -$55.8M | -$84.05M | |
| — | -1971.59% | -3722.07% | -1460.11% | -21670.89% | -12040.21% | -67.51% | — | |
| $24.4M | $26.26M | $34.76M | $31.03M | $8.77M | $826K | $3.38M | $8.74M | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$286.04M | -$276.48M | -$337.71M | -$341.97M | -$290.51M | -$363.87M | -$52.41M | -$75.31M | |
| — | -1800.58% | -3374.72% | -1338.66% | -21036.13% | -12012.94% | -63.41% | — | |
| — | — | — | — | — | -$363.87M | -$230.2M | -$75.31M | |
| -$286.69M | -$274.76M | -$338.5M | -$331.75M | -$299.84M | -$365.02M | -$52.67M | -$74.98M | |
| USD/shares | — | -$1.61 | -$2.36 | -$2.79 | -$2.59 | -$3.82 | -$5.40 | — |
| USD/shares | — | -$1.61 | -$2.36 | -$2.79 | -$2.59 | -$3.82 | -$5.40 | — |
| shares | — | 171.59M | 142.87M | 122.58M | 112.23M | 95.14M | 42.62M | 3.45M |
| shares | — | — | — | — | 112.23M | 95.14M | 42.62M | 3.45M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.76×
EV/EBIT
—
Peer median 23.88×
P/E (TTM)
—
Peer median 18.90×
Peer medians compare against the 203 similar-size Biotechnology companies (of 533 listed).
Key facts
CIK
1812364
CUSIP
75943R102
13F (30d)
254 filings
235 filers
Visit website
Investor relations